Duchenne Muscular Dystrophy (DMD) Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Duchenne Muscular Dystrophy (DMD) Treatment Market by drug class(Corticosteroids, Pain management drugs) by  distribution channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

The global Duchenne Muscular Dystrophy Treatment Market size was estimated at USD 3.8 Bn in 2021, growing at a CAGR of 38.2% during the forecast period 2021-2027. Duchenne muscular dystrophy (DMD) is a genetic disorder and it is one of the 9 types of muscular dystrophy, which is characterized by progressive degeneration and weakness of muscle. It is caused due to the absence of dystrophin protein which helps to keep muscle cells intact. The onset of symptoms will be from early childhood in the age of 3-5. Guillaume Benjamin Amand Duchenne was the first French neurologist to describe Duchenne muscular dystrophy in the 1860s. There is no known cure for Duchenne muscular dystrophy but the treatment is given to control the symptoms to maximize the quality of life of the patient. There are very few products are marketed for the treatment of Duchenne muscular dystrophy-like Translama, Exodus 51, and Emflaza. Presently this market is in the research phase majorly and focuses on the ongoing clinical trials for the development of innovative products. Government organizations are focussing on the prevention of Duchenne muscular dystrophy. For instance, world Duchenne awareness day was initiated by The United Parent Projects Muscular Dystrophy (UPPMD) with the motto of rising awareness regarding Duchenne muscular dystrophy globally and they have declared 07 th September as the world’s Duchenne awareness day. In 2015, U.S. FDA has published specific guidance for the development of drugs to treat Duchenne muscular dystrophy. Innovative approaches like utrophin modulation which is going to launch during the forecast period to treat DMD and approvals for the drugs such as ezutromid of summit therapeutics a phase II clinical trial drug which received orphan drug designation fast approval from U.S.FDA and BioMarin Pharmaceuticals is developing an exon-skipping drisapersen which is phase III clinical trial evaluation all these developments are expected to offer lucrative opportunities for Duchenne Muscular Dystrophy Treatment Market.

Duchenne Muscular Dystrophy Treatment Market

MARKET SUMMARY
-
38.2% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 38.2%
  • Largest Market– Europe
  • Fastest Growing Market– North America

Duchenne Muscular Dystrophy Treatment Market

  • In 2017 March, PTC Therapeutics entered into the purchase agreement with Marathon Pharmaceuticals for its Emflaza to treat DMD.
  • In February 2017, deflazacort (Emflaza) of marathon pharmaceuticals (Acquired by PTC Therapeutics) to treat DMD has received U.S.FDA approval.
  • In September 2016, U.S.FDA granted accelerated approval to Sarepta Therapeutics Eteplirsen (Exondys 51) a disease-modifying drug for treating DMD
Market Key Players
  • Bristol-Myers Squibb(U.S)
  • FibroGen, Inc (U.S)
  • ITALFARMACO S.p.A. (Italy)
  • Catabasis Pharmaceuticals, Inc.(U.S)
  • NS Pharma, Inc. (U.S)
  • Marathon Pharmaceuticals, LLC (U.S)
  • ReveraGen BioPharma, Inc. (U.S)
Drivers And Restraints

Duchenne Muscular Dystrophy Treatment Market

Increase in the prevalence rate of duchenne muscular dystrophy is the major factor expected to drive the market growth of Market. As per, NHS estimation 100 are born with duchenne muscular dystrophy every year in the UK, while 349 new cases were reported in the U.S. in 2010 as per to Centre for Disease Control. Furthermore, Increasing in healthcare expenditure and growing awareness about Duchenne muscular dystrophy is also propelling the growth of the Market. However, low treatment seeking rate because of delayed diagnosis and fast prognosis of the disorder are the factors which are restraining the growth of Duchenne muscular dystrophy.


Europe got significant share

Duchenne Muscular Dystrophy Treatment Market

On the basis of geographical regions, Duchenne Muscular Dystrophy Treatment Market is classified as into five key regions as Europe, Asia- Pacific, North America, Middle East & Africa and Latin America. The European region is the dominating market in global DMD treatment market owing to the several treatments for DMD which are approved and are under review in EU. For instance, PTC Therapeutics has recently received orphan drug designation and conditional approval for its Translarna, a gene therapy to treat DPD. North America holds a significant position in DMD treatment market owing to the high prevalence of DMD. Emerging markets like Asia Pacific, Latin America are expected to have significant growth rate owing to the growing prevalence of DMD, large patient pool and growing healthcare expenditure and awareness of DMD.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, and forecast from 2021-2027
  • The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments, and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Segmentation

Duchenne Muscular Dystrophy Treatment Market


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content

  1. Executive Summary
  2. Global Duchenne Muscular Dystrophy (DMD) Treatment Market Introduction
    • Global Duchenne Muscular Dystrophy (DMD) Treatment Market – Taxonomy
    • Global Duchenne Muscular Dystrophy (DMD) Treatment Market –Definitions
      • Drug Class
      • Distribution Channel
  1. Global Duchenne Muscular Dystrophy (DMD) Treatment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Duchenne Muscular Dystrophy (DMD) Treatment Market Dynamic Factors – Impact Analysis
    • Global Duchenne Muscular Dystrophy (DMD) Treatment Market – Competition Landscape
    • Epidemiology
  2. Global Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market OpportunityAnalysis
  3. Global Duchenne Muscular Dystrophy (DMD) Treatment Market, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Corticosteroids
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Pain management drugs
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Hospital Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Duchenne Muscular Dystrophy (DMD) Treatment Market – Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Region, 2018 – 2024
  2. North America Duchenne Muscular Dystrophy (DMD) Treatment MarketAnalysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Corticosteroids
      • Pain management drugs
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • US
      • Canada
    • North America Duchenne Muscular Dystrophy (DMD) Treatment Market – Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2018 – 2024
    • North America Duchenne Muscular Dystrophy (DMD) Treatment Market Dynamics – Trends
  3. Europe Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Corticosteroids
      • Pain management drugs
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Duchenne Muscular Dystrophy (DMD) Treatment Market – Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2018 – 2024
    • Europe Duchenne Muscular Dystrophy (DMD) Treatment Market Dynamics – Trends
  4. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Corticosteroids
      • Pain management drugs
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Duchenne Muscular Dystrophy (DMD) Treatment Market – Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2018 – 2024
    • Asia-Pacific Duchenne Muscular Dystrophy (DMD) Treatment Market Dynamics – Trends
  5. Latin America Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Corticosteroids
      • Pain management drugs
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Duchenne Muscular Dystrophy (DMD) Treatment Market – Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2018 – 2024
    • Latin America Duchenne Muscular Dystrophy (DMD) Treatment Market Dynamics – Trends
  6. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Corticosteroids
      • Pain management drugs
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Duchenne Muscular Dystrophy (DMD) Treatment Market – Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2018 – 2024
    • MEA Duchenne Muscular Dystrophy (DMD) Treatment Market Dynamics – Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Bristol-Myers Squibb(U.S)
      • FibroGen, Inc (U.S)
      • ITALFARMACO S.p.A. (Italy)
      • Catabasis Pharmaceuticals, Inc.(U.S)
      • NS Pharma, Inc. (U.S)
      • Marathon Pharmaceuticals, LLC (U.S)
      • ReveraGen BioPharma, Inc. (U.S)
      • Pfizer (U.S)
      • Summit Therapeutics plc (U.K)
      • Taiho Pharmaceutical Co (Japan)
      • Sarepta Therapeutics (U.S), Inc.
      • Santhera Pharmaceuticals
      • PTC Therapeutics (Switzerland).
  1. Research Methodology
  2. Key Assumptions and Acronyms

Disclaimer

The above mentioned segmentation is tentative; it is changed according to client’s requirement, or research feasibility.


Report

Company Profile

  • Bristol-Myers Squibb(U.S)
  • FibroGen, Inc (U.S)
  • ITALFARMACO S.p.A. (Italy)
  • Catabasis Pharmaceuticals, Inc.(U.S)
  • NS Pharma, Inc. (U.S)
  • Marathon Pharmaceuticals, LLC (U.S)
  • ReveraGen BioPharma, Inc. (U.S)
  • Pfizer (U.S)
  • Summit Therapeutics plc (U.K)
  • Taiho Pharmaceutical Co (Japan)
  • Sarepta Therapeutics, Inc. (U.S)
  • Santhera Pharmaceuticals
  • PTC Therapeutics (Switzerland)

Description

The global Duchenne Muscular Dystrophy Treatment Market size was estimated at USD 3.8 Bn in 2021, growing at a CAGR of 38.2% during the forecast period 2021-2027. Duchenne muscular dystrophy (DMD) is a genetic disorder and it is one of the 9 types of muscular dystrophy, which is characterized by progressive degeneration and weakness of muscle. It is caused due to the absence of dystrophin protein which helps to keep muscle cells intact. The onset of symptoms will be from early childhood in the age of 3-5. Guillaume Benjamin Amand Duchenne was the first French neurologist to describe Duchenne muscular dystrophy in the 1860s. There is no known cure for Duchenne muscular dystrophy but the treatment is given to control the symptoms to maximize the quality of life of the patient. There are very few products are marketed for the treatment of Duchenne muscular dystrophy-like Translama, Exodus 51, and Emflaza. Presently this market is in the research phase majorly and focuses on the ongoing clinical trials for the development of innovative products. Government organizations are focussing on the prevention of Duchenne muscular dystrophy. For instance, world Duchenne awareness day was initiated by The United Parent Projects Muscular Dystrophy (UPPMD) with the motto of rising awareness regarding Duchenne muscular dystrophy globally and they have declared 07 th September as the world’s Duchenne awareness day. In 2015, U.S. FDA has published specific guidance for the development of drugs to treat Duchenne muscular dystrophy. Innovative approaches like utrophin modulation which is going to launch during the forecast period to treat DMD and approvals for the drugs such as ezutromid of summit therapeutics a phase II clinical trial drug which received orphan drug designation fast approval from U.S.FDA and BioMarin Pharmaceuticals is developing an exon-skipping drisapersen which is phase III clinical trial evaluation all these developments are expected to offer lucrative opportunities for Duchenne Muscular Dystrophy Treatment Market.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX